FHTX stock falls 31% as trial halt triggers 40% staff cut
Alpha Vantage · Pluang · · AI-summarised by FinFlash
Pomerantz LLP is investigating Foghorn Therapeutics for potential securities fraud after the company announced it would not advance its FHD-909 trial or collaboration with Lilly and would cut its workforce by 40%. This news led to a 30.82% drop in Foghorn's stock price to $2.02 on October 2, 2026. The investigation aims to protect investors who suffered losses due to these developments.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.